DK2152879T3 - RNA antagonistforbindelser til modulering af beta-catenin - Google Patents
RNA antagonistforbindelser til modulering af beta-cateninInfo
- Publication number
- DK2152879T3 DK2152879T3 DK08749943.0T DK08749943T DK2152879T3 DK 2152879 T3 DK2152879 T3 DK 2152879T3 DK 08749943 T DK08749943 T DK 08749943T DK 2152879 T3 DK2152879 T3 DK 2152879T3
- Authority
- DK
- Denmark
- Prior art keywords
- catenin
- antagonist compounds
- modulating beta
- rna antagonist
- rna
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91537107P | 2007-05-01 | 2007-05-01 | |
| US2324408P | 2008-01-24 | 2008-01-24 | |
| PCT/EP2008/055365 WO2008132234A2 (en) | 2007-05-01 | 2008-04-30 | Rna antagonist compounds for the modulation of beta-catenin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2152879T3 true DK2152879T3 (da) | 2013-02-18 |
Family
ID=39926160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08749943.0T DK2152879T3 (da) | 2007-05-01 | 2008-04-30 | RNA antagonistforbindelser til modulering af beta-catenin |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20090005335A1 (enExample) |
| EP (1) | EP2152879B1 (enExample) |
| JP (2) | JP2010524486A (enExample) |
| KR (1) | KR20100024399A (enExample) |
| CN (1) | CN101842483A (enExample) |
| AU (1) | AU2008244211B2 (enExample) |
| CA (1) | CA2685444A1 (enExample) |
| DK (1) | DK2152879T3 (enExample) |
| EA (1) | EA018986B1 (enExample) |
| ES (1) | ES2399371T3 (enExample) |
| IL (1) | IL201865A0 (enExample) |
| MX (1) | MX2009011878A (enExample) |
| NZ (1) | NZ581200A (enExample) |
| TW (1) | TW200848077A (enExample) |
| WO (1) | WO2008132234A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2152879T3 (da) * | 2007-05-01 | 2013-02-18 | Santaris Pharma As | RNA antagonistforbindelser til modulering af beta-catenin |
| EP2490767A4 (en) * | 2009-07-15 | 2013-02-13 | Santaris Pharma As | OBJECTIVE RNA ANTAGONISTS FOR THE TREATMENT OF LEUKEMIA ON GLI2 |
| DK2591105T3 (en) | 2010-07-06 | 2017-07-31 | Dicerna Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR SPECIFIC INHIBITION OF BETA-CATENIN USING DOUBLE-STRENGTH RNA |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| US9920317B2 (en) | 2010-11-12 | 2018-03-20 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
| US20140323557A1 (en) * | 2011-11-11 | 2014-10-30 | Santaris Pharma A/S | Compounds for the modulation of beta-catenin expression and uses thereof |
| BR112014016870A2 (pt) | 2012-01-09 | 2017-06-27 | Huesken Dieter | composições orgânicas para tratar doenças relacionadas com beta-catenina |
| CN104583398A (zh) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节基因表达的组合物和方法 |
| US10837014B2 (en) | 2012-05-16 | 2020-11-17 | Translate Bio Ma, Inc. | Compositions and methods for modulating SMN gene family expression |
| CN104583402A (zh) | 2012-05-16 | 2015-04-29 | Rana医疗有限公司 | 用于调节mecp2表达的组合物和方法 |
| CA2889044A1 (en) | 2012-11-15 | 2014-05-22 | Roche Innovation Center Copenhagen A/S | Anti apob antisense conjugate compounds |
| CA2893801A1 (en) * | 2013-01-30 | 2014-08-07 | F. Hoffmann-La Roche Ag | Lna oligonucleotide carbohydrate conjugates |
| JP2016518842A (ja) | 2013-05-01 | 2016-06-30 | レグルス セラピューティクス インコーポレイテッド | マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法 |
| EP2992096B1 (en) | 2013-05-01 | 2021-03-03 | Regulus Therapeutics Inc. | Compounds and methods for enhanced cellular uptake |
| WO2015026346A1 (en) | 2013-08-22 | 2015-02-26 | Hewlett Packard Development Company, L.P. | Projective computing system |
| TWI657755B (zh) * | 2013-12-30 | 2019-05-01 | Philip Morris Products S. A. | 包含隔熱可燃熱源之煙品 |
| JP2017506259A (ja) | 2014-02-03 | 2017-03-02 | イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム・リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． | 幹細胞を枯渇させるためのカゼインキナーゼｉ阻害剤の使用 |
| WO2016070060A1 (en) | 2014-10-30 | 2016-05-06 | The General Hospital Corporation | Methods for modulating atrx-dependent gene repression |
| US10900036B2 (en) | 2015-03-17 | 2021-01-26 | The General Hospital Corporation | RNA interactome of polycomb repressive complex 1 (PRC1) |
| US11643655B2 (en) * | 2016-11-15 | 2023-05-09 | City Of Hope | Methods for intracellular delivery and enhanced gene targeting |
| EP3579890B1 (en) | 2017-02-09 | 2025-06-18 | Femasys Inc. | Methods and compositions comprising biodegradable cyanoacrylates |
| TWI854980B (zh) | 2018-05-08 | 2024-09-11 | 美商雷格勒斯治療公司 | 用於調節mir-122之微小rna化合物及方法 |
| EP4441224A4 (en) * | 2021-12-03 | 2026-03-11 | Quralis Corp | Antisense oligonucleotides with modified skeletal chemicals |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4962029A (en) | 1987-10-02 | 1990-10-09 | Cetus Corporation | Covalent oligonucleotide-horseradish peroxidase conjugate |
| US4914210A (en) | 1987-10-02 | 1990-04-03 | Cetus Corporation | Oligonucleotide functionalizing reagents |
| US6066500A (en) | 1999-06-25 | 2000-05-23 | Isis Pharmaceuticals Inc. | Antisense modulation of Beta catenin expression |
| US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
| US20030064384A1 (en) * | 2001-04-02 | 2003-04-03 | Mien-Chie Hung | Beta-catenin is a strong and independent prognostic factor for cancer |
| US20030143586A1 (en) | 2001-10-12 | 2003-07-31 | Qimin Chao | Genetic hypermutability of plants for gene discovery and diagnosis |
| US7087229B2 (en) | 2003-05-30 | 2006-08-08 | Enzon Pharmaceuticals, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| EP2305813A3 (en) | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| EP2284269B1 (en) | 2002-11-18 | 2017-08-09 | Roche Innovation Center Copenhagen A/S | Antisense design |
| AU2004230927B9 (en) | 2003-04-13 | 2011-12-01 | Enzon Pharmaceuticals, Inc. | Polymeric oligonucleotide prodrugs |
| US20050136395A1 (en) * | 2003-05-08 | 2005-06-23 | Affymetrix, Inc | Methods for genetic analysis of SARS virus |
| US20070009899A1 (en) * | 2003-10-02 | 2007-01-11 | Mounts William M | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases |
| WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
| CA2622583A1 (en) | 2005-09-15 | 2007-03-22 | Henrik Frydenlund Hansen | Rna antagonist compounds for the inhibition of apo-b100 expression |
| EP2505646A1 (en) | 2006-05-05 | 2012-10-03 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression of CRP |
| WO2008034122A2 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| CA2662520A1 (en) | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| WO2008053314A2 (en) | 2006-10-30 | 2008-05-08 | Nokia Corporation | Method, apparatus and system providing operator controlled mobility for user equipment |
| DK2152879T3 (da) | 2007-05-01 | 2013-02-18 | Santaris Pharma As | RNA antagonistforbindelser til modulering af beta-catenin |
-
2008
- 2008-04-30 DK DK08749943.0T patent/DK2152879T3/da active
- 2008-04-30 CN CN200880022871A patent/CN101842483A/zh active Pending
- 2008-04-30 NZ NZ581200A patent/NZ581200A/en not_active IP Right Cessation
- 2008-04-30 MX MX2009011878A patent/MX2009011878A/es active IP Right Grant
- 2008-04-30 WO PCT/EP2008/055365 patent/WO2008132234A2/en not_active Ceased
- 2008-04-30 KR KR1020097025006A patent/KR20100024399A/ko not_active Ceased
- 2008-04-30 EA EA200971013A patent/EA018986B1/ru not_active IP Right Cessation
- 2008-04-30 EP EP08749943A patent/EP2152879B1/en active Active
- 2008-04-30 CA CA002685444A patent/CA2685444A1/en not_active Abandoned
- 2008-04-30 JP JP2010504745A patent/JP2010524486A/ja active Pending
- 2008-04-30 US US12/113,031 patent/US20090005335A1/en not_active Abandoned
- 2008-04-30 ES ES08749943T patent/ES2399371T3/es active Active
- 2008-04-30 TW TW097116039A patent/TW200848077A/zh unknown
- 2008-04-30 AU AU2008244211A patent/AU2008244211B2/en not_active Ceased
-
2009
- 2009-01-21 US US12/356,923 patent/US7915401B2/en not_active Expired - Fee Related
- 2009-11-01 IL IL201865A patent/IL201865A0/en unknown
-
2010
- 2010-09-02 US US12/874,668 patent/US8039446B2/en not_active Expired - Fee Related
-
2011
- 2011-09-14 US US13/232,123 patent/US20120004288A1/en not_active Abandoned
-
2014
- 2014-06-18 JP JP2014125205A patent/JP2014209915A/ja not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010524486A (ja) | 2010-07-22 |
| EP2152879B1 (en) | 2012-11-14 |
| US20120004288A1 (en) | 2012-01-05 |
| JP2014209915A (ja) | 2014-11-13 |
| WO2008132234A3 (en) | 2009-05-07 |
| MX2009011878A (es) | 2010-01-25 |
| EA200971013A1 (ru) | 2010-04-30 |
| US20090005335A1 (en) | 2009-01-01 |
| US7915401B2 (en) | 2011-03-29 |
| US20090203137A1 (en) | 2009-08-13 |
| EP2152879A2 (en) | 2010-02-17 |
| AU2008244211B2 (en) | 2014-08-21 |
| CN101842483A (zh) | 2010-09-22 |
| US8039446B2 (en) | 2011-10-18 |
| CA2685444A1 (en) | 2008-11-06 |
| ES2399371T3 (es) | 2013-03-27 |
| KR20100024399A (ko) | 2010-03-05 |
| AU2008244211A1 (en) | 2008-11-06 |
| NZ581200A (en) | 2012-04-27 |
| EA018986B1 (ru) | 2013-12-30 |
| IL201865A0 (en) | 2011-08-01 |
| US20110086902A1 (en) | 2011-04-14 |
| WO2008132234A2 (en) | 2008-11-06 |
| WO2008132234A4 (en) | 2009-07-09 |
| TW200848077A (en) | 2008-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2004635I2 (lt) | Pakeistieji enaminokarbonilo junginiai | |
| DE602007011793D1 (de) | Biaryl-ether-harnstoffverbindungen | |
| DK2149605T3 (da) | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA | |
| DK2185567T3 (da) | Substituerede bicyclolactam-forbindelser | |
| BRPI0813500A2 (pt) | Compostos antivirais | |
| DK2068927T3 (da) | Fremgangsmåder til reducering af eosinofilniveauer | |
| BRPI0821086A2 (pt) | Compostos inseticidas | |
| BRPI0811156A2 (pt) | compostos antagonistas de rna para a modulação de her3 | |
| DK2110987T3 (da) | Udvidelse af trafikindikation for forbindelsesfejlhåndtering | |
| BRPI0815042A2 (pt) | Compostos de pirazol | |
| DK2334639T3 (da) | Fremgangsmåder til fremstilling af aminosulfonforbindelser | |
| BRPI0813653A2 (pt) | Compostos de imidazotiazol moduladores de sirtuína | |
| BRPI0813651A2 (pt) | Compostos de tiazolopiridina moduladores de sirtuína | |
| DK2126801T3 (da) | Fremgangsmåde til udvælgelse af information | |
| BRPI0811264A2 (pt) | Compostos | |
| DE112008002590A5 (de) | Mikroreaktor | |
| DK3106875T3 (da) | Fremgangsmåde til detektering af cancer | |
| BRPI0814424A2 (pt) | Compostos heterociclila | |
| BRPI0809996A2 (pt) | Compostos | |
| DK2126602T3 (da) | Tilvejebringelse af hjælpedata | |
| BRPI0816512A2 (pt) | Cartucho de tinta | |
| BRPI0817149A2 (pt) | Cartucho de tinta | |
| BRPI0815181A2 (pt) | Compostos | |
| BRPI0811597A2 (pt) | compostos de arilamida pirimidona | |
| DK2337627T3 (da) | Fremgangsmåde til fremstilling af monodispergerede emulsioner |